Literature DB >> 12775733

Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival.

D Ratschiller1, J Heighway, M Gugger, A Kappeler, F Pirnia, R A Schmid, M M Borner, D C Betticher.   

Abstract

PURPOSE: Cyclin D1 is overexpressed in almost 60% of resectable non-small-cell lung cancer (NSCLC). In the absence of cyclin D1 gene amplification, overexpression is characterized by allelic imbalanced transcript levels.
METHODS: The aims were to study cyclin D1 expression by immunohistochemistry and allelic balance of transcripts in tumor-free bronchial epithelia from patients with resectable NSCLC by using monoclonal antibodies (48 patients and 288 sites), microdissection/reverse transcriptase polymerase chain reaction/restriction fragment length polymorphism analyses (24 patients and 144 sites). Derived data were related to patient characteristics-in particular, smoking habits.
RESULTS: In 167 (58%) of 288 sites, cyclin D1 was overexpressed, with cytoplasmic and nuclear sublocalization in 53% and 7% of all sites, respectively. Nuclear overexpression was more frequent in premalignant versus normal or hyperplastic epithelia (55% v 3%; P <.0001). Allele-specific expression imbalances were found in 69 (48%) of 144 sites; in particular, those in which cyclin D1 was overexpressed (P =.004). In 14 (58%) of 24 patients, balanced or imbalanced transcript ratios and degree of expression were consistent at all sites for the same patient, whereas in another 10 patients, transcript balances and cyclin D1 expression patterns varied across the sites. Nuclear cyclin D1 expression in at least one site (14 of 48 patients) was linked to heavy smoking (> 40 pack-years; P =.02) and shorter overall survival (P =.01).
CONCLUSION: Allele-specific, probably damage-driven, deregulation of the cyclin D1 gene may precede and perhaps facilitate the spread of preneoplastic clones across the bronchial epithelial surface in a significant number of patients. Cyclin D1 expression at multiple bronchial sites may identify a subgroup of heavy-smoking patients with poor outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775733     DOI: 10.1200/JCO.2003.03.103

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Authors:  Konstantin H Dragnev; Tian Ma; Jobin Cyrus; Fabrizio Galimberti; Vincent Memoli; Alexander M Busch; Gregory J Tsongalis; Marc Seltzer; David Johnstone; Cherie P Erkmen; William Nugent; James R Rigas; Xi Liu; Sarah J Freemantle; Jonathan M Kurie; Samuel Waxman; Ethan Dmitrovsky
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Jinming Yu; Xiaorong Sun; Dianbin Mu; Anqin Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

3.  MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells.

Authors:  Haifeng Wang; Changxing Ke; Xingyong Ma; Qinghua Zhao; Mingying Yang; Wei Zhang; Jiansong Wang
Journal:  Tumour Biol       Date:  2016-11-09

4.  Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.

Authors:  Nagaraj S Nagathihalli; Pierre P Massion; Adriana L Gonzalez; Pengcheng Lu; Pran K Datta
Journal:  Mol Cancer Ther       Date:  2012-08-29       Impact factor: 6.261

5.  The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

Authors:  M J Labonte; P M Wilson; D Yang; W Zhang; R D Ladner; Y Ning; A Gerger; P O Bohanes; L Benhaim; R El-Khoueiry; A El-Khoueiry; H-J Lenz
Journal:  Ann Oncol       Date:  2011-10-11       Impact factor: 32.976

6.  Combinations of indole-3-carbinol and silibinin suppress inflammation-driven mouse lung tumorigenesis by modulating critical cell cycle regulators.

Authors:  Jung Min Song; Xuemin Qian; Kalkidan Molla; Fistum Teferi; Pramod Upadhyaya; Gerry O Sullivan; Xianghua Luo; Fekadu Kassie
Journal:  Carcinogenesis       Date:  2015-04-20       Impact factor: 4.944

7.  Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA.

Authors:  Hu Huang; Yi-de Hu; Na Li; Yong Zhu
Journal:  Oligonucleotides       Date:  2009-06

8.  SCC-S2 is overexpressed in colon cancers and regulates cell proliferation.

Authors:  Zhifeng Miao; Tingting Zhao; Zhenning Wang; Yingying Xu; Yongxi Song; Jianhua Wu; Huimian Xu
Journal:  Tumour Biol       Date:  2012-08-12

9.  Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Authors:  Clay E S Comstock; Michael A Augello; Ruth Pe Benito; Jason Karch; Thai H Tran; Fransiscus E Utama; Elizabeth A Tindall; Ying Wang; Craig J Burd; Eric M Groh; Hoa N Hoang; Graham G Giles; Gianluca Severi; Vanessa M Hayes; Brian E Henderson; Loic Le Marchand; Laurence N Kolonel; Christopher A Haiman; Raffaele Baffa; Leonard G Gomella; Erik S Knudsen; Hallgeir Rui; Susan M Henshall; Robert L Sutherland; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

10.  Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.

Authors:  Tian Ma; Fabrizio Galimberti; Cherie P Erkmen; Vincent Memoli; Fadzai Chinyengetere; Lorenzo Sempere; Jan H Beumer; Bean N Anyang; William Nugent; David Johnstone; Gregory J Tsongalis; Jonathan M Kurie; Hua Li; James Direnzo; Yongli Guo; Sarah J Freemantle; Konstantin H Dragnev; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2013-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.